Pasithea Therapeutics (KTTA) Earnings Analysis
Pasithea Therapeutics (KTTA) next reports earnings on 2026-08-13, consensus EPS -0.16 USD. Last quarter (2026-05-15) it beat with EPS -0.12 USD vs -0.45 USD est (+73.3%). It has beaten estimates in 2/3 recent quarters (67%). Trailing P/E -0.19.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does KTTA next report earnings?
| Next earnings date | 2026-08-13 |
|---|---|
| Consensus EPS estimate | -0.16 USD |
| Revenue estimate | 0.00B |
KTTA earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-15 | -0.12 USD | -0.45 USD | +73.3% | Beat |
| 2026-03-30 | -0.89 USD | -0.18 USD | -394.4% | Miss |
| 2026-02-25 | -0.18 USD | -0.18 USD | 0% | Beat |
| 2025-11-13 | -0.41 USD | n/a | n/a | n/a |
| 2025-08-14 | -0.66 USD | n/a | n/a | n/a |
| 2025-05-15 | -1.61 USD | n/a | n/a | n/a |
| 2025-03-24 | -2.41 USD | n/a | n/a | n/a |
Beat rate: 2/3 (67%) over reported quarters with consensus data.
KTTA valuation and analyst view
| Trailing P/E | -0.19 |
|---|---|
| Trailing EPS | -2.8067 USD |
| Price / book | 0.06 |
| Dividend yield | 0.00% |
| Market cap | 0.00B |
| Analyst consensus | Buy (2 buy / 0 hold / 0 sell) |
| Avg price target | 3 USD |
Related research pages
Frequently asked questions
When is Pasithea Therapeutics (KTTA)'s next earnings date?
Pasithea Therapeutics is next scheduled to report on 2026-08-13, with a consensus EPS estimate of -0.16 USD and revenue estimate of 0.00B.
Did KTTA beat earnings last quarter?
In its 2026-05-15 report, KTTA posted EPS of -0.12 USD versus a -0.45 USD estimate — a beat of 73.3%.
What is KTTA's earnings track record?
Over the last 3 reported quarters with consensus data, KTTA beat estimates 2 times (67%).
What is KTTA's current P/E ratio and EPS?
KTTA trades at a trailing P/E of -0.19 on trailing EPS of -2.8067027449864885 USD.
What do analysts rate KTTA?
Analyst consensus is "Buy" across 2 ratings (0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 3 USD.